- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00001049
A Study of Didanosine Use Alone or in Combination With Zidovudine in Infants Exposed to or Infected With HIV
A Phase I Evaluation of the Safety and Toxicity of Zidovudine and Didanosine in Combination in HIV-Infected or Exposed Infants and a Phase II Study of the Effect of Didanosine vs. Combination Therapy With Zidovudine and Didanosine on HIV-1 RNA in Infants With HIV Infection
To determine the pharmacokinetics, safety, and efficacy of didanosine (ddI) alone or in combination with zidovudine (AZT) in HIV-infected infants.
PER AMENDMENT 4/8/97: Part A study objectives are completed. Part B objectives: To assess the safety, toxicity, and tolerability and to compare anti-HIV activity, as measured by change in log10 RNA, of the two study arms.
Early treatment of HIV-infected infants with antiretroviral agents may prevent the early and rapid decline of CD4 count and immunologic function. Combination therapy may be preferred over monotherapy, since resistance to a single agent can develop rapidly. Currently, there is little information on ddI monotherapy in young infants less than 90 days and no information on the use of combination therapy in this population.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Early treatment of HIV-infected infants with antiretroviral agents may prevent the early and rapid decline of CD4 count and immunologic function. Combination therapy may be preferred over monotherapy, since resistance to a single agent can develop rapidly. Currently, there is little information on ddI monotherapy in young infants less than 90 days and no information on the use of combination therapy in this population.
In Part A, a cohort of patients younger than 28 days (was less than 120 days; amended 6/20/95) of age receives open-label ddI monotherapy for 1 week before initiation of AZT/ddI combination therapy. After pharmacokinetic data are obtained, an additional cohort of patients receives ddI at a higher dose. An age-adjusted dose for ddI is determined for use in Part B. (NOTE: As of 2/13/95, Part A has completed accrued for infants 29 to 120 days of age.) Part B patients less than 90 days of age (was less than 180 days of age; amended 6/20/95) are randomized, on a double-blind basis, to receive ddI or AZT/ddI. All patients continue treatment until 12 months after the last patient on Part B is enrolled. PER AMENDMENT 4/8/97: Part A of this protocol is closed with accrual objectives met. Part B of the study will remain open for patient accrual until 6/2/97. Part B is designed as a 2-arm, randomized, double-blind study to assess safety, toxicity and tolerability as well as anti-HIV activity of ddI or AZT/ddI.
Type d'étude
Inscription
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
-
San Juan, Porto Rico, 009367344
- San Juan City Hosp
-
San Juan, Porto Rico, 009365067
- Univ of Puerto Rico / Univ Children's Hosp AIDS
-
-
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35294
- Univ of Alabama at Birmingham Schl of Med / Pediatrics
-
-
California
-
La Jolla, California, États-Unis, 920930672
- UCSD Med Ctr / Pediatrics / Clinical Sciences
-
Long Beach, California, États-Unis, 90801
- Long Beach Memorial (Pediatric)
-
Los Angeles, California, États-Unis, 90033
- Los Angeles County - USC Med Ctr
-
Los Angeles, California, États-Unis, 905022004
- Harbor - UCLA Med Ctr / UCLA School of Medicine
-
Oakland, California, États-Unis, 946091809
- Children's Hosp of Oakland
-
San Francisco, California, États-Unis, 94110
- San Francisco Gen Hosp
-
San Francisco, California, États-Unis, 941430105
- UCSF / Moffitt Hosp - Pediatric
-
-
Colorado
-
Denver, Colorado, États-Unis, 802181088
- Children's Hosp of Denver
-
-
Connecticut
-
Farmington, Connecticut, États-Unis, 06032
- Univ of Connecticut / Farmington
-
-
District of Columbia
-
Washington, District of Columbia, États-Unis, 200102916
- Children's Hosp of Washington DC
-
Washington, District of Columbia, États-Unis, 20060
- Howard Univ Hosp
-
-
Florida
-
Fort Lauderdale, Florida, États-Unis, 33311
- North Broward Hosp District
-
Jacksonville, Florida, États-Unis, 32209
- Univ of Florida Health Science Ctr / Pediatrics
-
Miami, Florida, États-Unis, 33161
- Univ of Miami (Pediatric)
-
Riviera Beach, Florida, États-Unis, 33404
- Palm Beach County Health Dept
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60612
- Cook County Hosp
-
Chicago, Illinois, États-Unis, 606143394
- Chicago Children's Memorial Hosp
-
Chicago, Illinois, États-Unis, 606371470
- Univ of Chicago Children's Hosp
-
Chicago, Illinois, États-Unis, 60612
- Univ of Illinois College of Medicine / Pediatrics
-
-
Louisiana
-
New Orleans, Louisiana, États-Unis, 701122699
- Tulane Univ / Charity Hosp of New Orleans
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21201
- Univ of Maryland at Baltimore / Univ Med Ctr
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 021155724
- Children's Hosp of Boston
-
Springfield, Massachusetts, États-Unis, 01199
- Baystate Med Ctr of Springfield
-
Worcester, Massachusetts, États-Unis, 016550001
- Univ of Massachusetts Med School
-
-
Michigan
-
Detroit, Michigan, États-Unis, 48201
- Children's Hosp of Michigan
-
-
New Jersey
-
Newark, New Jersey, États-Unis, 071032714
- Univ of Medicine & Dentistry of New Jersey / Univ Hosp
-
Newark, New Jersey, États-Unis, 07103
- Saint Joseph's Hosp and Med Ctr/UMDNJ - New Jersey Med Schl
-
Newark, New Jersey, États-Unis, 071072198
- Children's Hosp of New Jersey / UMDNJ - New Jersey Med Schl
-
-
New York
-
Albany, New York, États-Unis, 12208
- Children's Hosp at Albany Med Ctr
-
Bronx, New York, États-Unis, 10457
- Bronx Lebanon Hosp Ctr
-
New Hyde Park, New York, États-Unis, 11040
- Schneider Children's Hosp
-
New York, New York, États-Unis, 10029
- Metropolitan Hosp Ctr
-
New York, New York, États-Unis, 10032
- Columbia Presbyterian Med Ctr
-
New York, New York, États-Unis, 10032
- Incarnation Children's Ctr / Columbia Presbyterian Med Ctr
-
New York, New York, États-Unis, 10037
- Harlem Hosp Ctr
-
New York, New York, États-Unis, 10029
- Mount Sinai Med Ctr / Pediatrics
-
Rochester, New York, États-Unis, 14642
- Univ of Rochester Medical Center
-
Syracuse, New York, États-Unis, 13210
- SUNY Health Sciences Ctr at Syracuse / Pediatrics
-
-
North Carolina
-
Durham, North Carolina, États-Unis, 277103499
- Duke Univ Med Ctr
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 191044318
- Children's Hosp of Philadelphia
-
Philadelphia, Pennsylvania, États-Unis, 191341095
- Saint Christopher's Hosp for Children
-
-
South Carolina
-
Charleston, South Carolina, États-Unis, 294253312
- Med Univ of South Carolina
-
-
Virginia
-
Norfolk, Virginia, États-Unis, 23507
- Children's Hosp of the King's Daughters
-
Richmond, Virginia, États-Unis, 23219
- Med College of Virginia
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria
Concurrent Medication:
Recommended:
- PCP prophylaxis.
Allowed:
- Acetaminophen if not on a continual basis.
NOTE:
- Drugs that are metabolized by hepatic glucuronidation or that are associated with occurrence of pancreatitis are allowed but should be used with caution.
Patients must have at least one of the following:
- Documented HIV infection.
- Been born to an HIV-infected woman and receiving AZT.
PER AMENDMENT 4/8/97:
- Number 2 above no longer required with closure of Part A of study.
- Patients must have signed, informed consent of parent or legal guardian.
PER 6/20/95 AMENDMENT, patients in Part A must be less than 28 days of age and those in Part B must be less than 90 days of age.
PER 7/7/94 AMENDMENT, patients in Part A were less than 120 days of age and those in Part B were less than 180 days of age.
NOTE:
- All patients must have been more than 34 weeks gestation at birth.
Prior Medication:
Allowed:
- Prior vaccine therapy.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
- Pancreatitis.
- Clinically unstable condition.
- Current participation on a vaccine trial or, for Part A, a perinatal trial if of indeterminate infection status.
Concurrent Medication:
Excluded:
- Vaccine therapy.
Patients with the following prior condition are excluded:
- Pancreatitis at any time since birth.
Prior Medication:
Excluded in Part B patients only:
- More than 90 days of prior antiretroviral or immunomodulator therapy, exclusive of therapy received in utero.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Masquage: Double
Collaborateurs et enquêteurs
Les enquêteurs
- Chaise d'étude: A Kovacs
- Chaise d'étude: R Husson
Publications et liens utiles
Publications générales
- McKinney RE Jr. Ongoing and future trials of antiretroviral therapy in the pediatric AIDS clinical trials group (PACTG). Conf Retroviruses Opportunistic Infect. 1996 Jan 28-Feb 1;3rd:173
Dates d'enregistrement des études
Dates principales de l'étude
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Infections par virus à ARN
- Maladies virales
- Infections transmissibles par le sang
- Maladies transmissibles
- Maladies sexuellement transmissibles, virales
- Maladies sexuellement transmissibles
- Infections à lentivirus
- Infections à rétroviridae
- Syndromes d'immunodéficience
- Maladies du système immunitaire
- Maladies à virus lents
- Infections à VIH
- Infections
- Syndrome immunodéficitaire acquis
- Mécanismes moléculaires de l'action pharmacologique
- Agents anti-infectieux
- Agents antiviraux
- Inhibiteurs de la transcriptase inverse
- Inhibiteurs de la synthèse des acides nucléiques
- Inhibiteurs d'enzymes
- Agents anti-VIH
- Agents antirétroviraux
- Antimétabolites
- Zidovudine
- Didanosine
Autres numéros d'identification d'étude
- ACTG 239
- 11216 (DAIDS ES Registry Number)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .